Cargando…
Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of ther...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488842/ https://www.ncbi.nlm.nih.gov/pubmed/29653948 http://dx.doi.org/10.1183/16000617.0004-2018 |
_version_ | 1784792750437171200 |
---|---|
author | Savale, Laurent Guignabert, Christophe Weatherald, Jason Humbert, Marc |
author_facet | Savale, Laurent Guignabert, Christophe Weatherald, Jason Humbert, Marc |
author_sort | Savale, Laurent |
collection | PubMed |
description | Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future. |
format | Online Article Text |
id | pubmed-9488842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94888422022-11-14 Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era Savale, Laurent Guignabert, Christophe Weatherald, Jason Humbert, Marc Eur Respir Rev Series Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) include different cardiopulmonary disorders in which the interaction of multiple genes with environmental and behavioural factors modulates the onset and the progression of these severe conditions. Although the development of therapeutic agents that modulate abnormalities in three major pathobiological pathways for PAH has revolutionised our approach to the treatment of PAH, the long-term survival rate remains unsatisfactory. Accumulating evidence has underlined that clinical outcomes and responses to therapy in PAH are modified by multiple factors, including genetic variations, which will be different for each individual. Since precision medicine, also known as stratified medicine or personalised medicine, aims to better target intervention to the individual while maximising benefit and minimising harm, it has significant potential advantages. This article aims to assemble and discuss the different initiatives that are currently underway in the PH/PAH fields together with the opportunities and prospects for their use in the near future. European Respiratory Society 2018-04-13 /pmc/articles/PMC9488842/ /pubmed/29653948 http://dx.doi.org/10.1183/16000617.0004-2018 Text en Copyright ©ERS 2018. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Series Savale, Laurent Guignabert, Christophe Weatherald, Jason Humbert, Marc Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title_full | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title_fullStr | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title_full_unstemmed | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title_short | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
title_sort | precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era |
topic | Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488842/ https://www.ncbi.nlm.nih.gov/pubmed/29653948 http://dx.doi.org/10.1183/16000617.0004-2018 |
work_keys_str_mv | AT savalelaurent precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera AT guignabertchristophe precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera AT weatheraldjason precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera AT humbertmarc precisionmedicineandpersonalisingtherapyinpulmonaryhypertensionseeingthelightfromthedawnofanewera |